Updated:
Life Science Innovations
Founded in Bialystok, Poland, Life Science Innovations addresses a specific gap in the Central European venture landscape: the translation of academic...
Life Science Innovations
Founded in Bialystok, Poland, Life Science Innovations addresses a specific gap in the Central European venture landscape: the translation of academic bio-science and med-tech research into investable commercial entities. The firm does not operate as a broad-based generalist fund. It concentrates on a narrow corridor — life sciences, digital health — in a geography where specialized seed-stage capital is thinner than in hubs like London or Berlin. The firm's model merges direct seed and start-up investments with a spin-off engine, systematically reviewing IP emerging from Polish and regional research institutions. This creates a pipeline of ventures in digital health, healthcare services, and applied AI for diagnostics. While specific portfolio names remain unpublished in the public record, the firm's stated stage focus spans seed through early-stage, allowing it to shape cap tables before traditional venture series arrive. Its footprint is primarily domestic Polish and neighboring Central European markets, leveraging local scientific talent pools and lower operating-cost bases for portfolio companies. As a specialized private equity firm rather than a single-family office, Life Science Innovations funnels institutional and private co-investor capital into its focus area. The team size and current asset base are not publicly disclosed, reflecting the firm's status as an early-stage manager in an emerging-market private equity context. Without published vehicle closings or team profiles, firm attributes remain inferred from its narrow sector commitment and regionally targeted sourcing lens. Life Science Innovations' structural differentiator lies in its origin — an asset manager built within Bialystok, not Warsaw, explicitly to capture underfunded academic spin-out opportunities in a region where banking and traditional venture remain risk-averse to pre-revenue science. The firm's entire mandate functions as an on-ramp from laboratory to institutional venture, a role few competitors in the region occupy with equal single-mindedness.
General information
Firm type
Private Equity
Location
Region
Europe
Country
Poland
City
Bialystok, Poland
Corporate office
ul. Żurawia 7, 15-540 Białystok, Poland
Principals
Adam Cudny
General Partner, Investment Committee
Marcin Szumowski
Investment Committee
Piotr Jeleński
Investment Committee
Paweł Wilski
CEO
Sector focus
Frequently asked questions
Who makes investment decisions at Life Science Innovations?
Investment decisions are governed by an Investment Committee. Publicly named committee members include Adam Cudny (General Partner), Marcin Szumowski (PhD), and Piotr Jeleński. CEO Paweł Wilski is also identified as part of the leadership team.
What investment stages does Life Science Innovations target?
The firm concentrates on early-stage ventures, specifically seed, start-up, and spin-off companies emerging from academic or laboratory research settings. The strategy does not indicate any later-stage growth equity or buyout mandate.
Which sectors is Life Science Innovations actively involved in?
The firm outlines four areas: healthcare and preventive medicine innovations, environmental protection with climate-positive or low-emission technology, biotechnology for lab diagnostics and agriculture, and medtech covering devices, biomaterials, and health IT solutions.
How is Life Science Innovations funded?
In addition to private capital, the firm is a beneficiary of the European Union's 2014-2020 Smart Growth Operational Programme, co-financed by the European Regional Development Fund. This public co-financing structure is a distinct feature of its capital base, aligning with its mission to support regional innovation.
Which companies has Life Science Innovations backed?
The firm discloses two portfolio companies on its website: AIDMED, which focuses on digital health and medical technology solutions, and Health2Organ, a biotechnology venture. The full portfolio size is not publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: